Press release
Castrate Resistant Prostrate Cancer Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024
Discover the latest drugs and treatment options in the Castrate Resistant Prostrate Cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ Castrate Resistant Prostrate Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/castrate-resistant-prostrate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Castrate Resistant Prostrate Cancer Pipeline Report
* In September 2024:- Bayer - A Single-arm, Open-label Phase 4 Study of Darolutamide in Addition to Standard Androgen Deprivation Therapy for Participants in India With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC).
* DelveInsight's Castrate Resistant Prostrate Cancer pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Castrate Resistant Prostrate Cancer treatment.
* The leading Castrate Resistant Prostrate Cancer Companies such as Janseen, Bristol-Myers Squibb, AB Science, Newsoara Biopharma, ESSA Pharma , and others.
* Promising Castrate Resistant Prostrate Cancer Therapies such as Etrumadenant, Zimberelimab, Quemliclustat, PF-06821497, Pembrolizumab , and others.
Stay ahead with the most recent pipeline outlook for Castrate Resistant Prostrate Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Castrate Resistant Prostrate Cancer Treatment Drugs [https://www.delveinsight.com/sample-request/castrate-resistant-prostrate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Castrate Resistant Prostrate Cancer Emerging Drugs
* Niraparib: Janseen
Niraparib is highly selective poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor, with potent activity against PARP-1 and PARP-2 deoxyribonucleic acid (DNA)-repair polymerases. Niraparib is currently investigated by Janssen Research & Development.
* Nivolumab: Bristol-Myers Squibb
Nivolumab by Bristol-Myers Squibb is a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1, with immune checkpoint inhibitory and antineoplastic activities. BMS is working on assessing the clinical activity seen with Nivolumab in combination with docetaxel in male patients with metastatic castration-resistant prostate cancer.
Explore groundbreaking therapies and clinical trials in the Castrate Resistant Prostrate Cancer Pipeline. Access DelveInsight's detailed report now! @ New Castrate Resistant Prostrate Cancer Drugs [https://www.delveinsight.com/sample-request/castrate-resistant-prostrate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Castrate Resistant Prostrate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* intravitreal
* Subretinal
* Topical.
* Molecule Type
Castrate Resistant Prostrate Cancer Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type
Unveil the future of Castrate Resistant Prostrate Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Castrate Resistant Prostrate Cancer Market Drivers and Barriers [https://www.delveinsight.com/sample-request/castrate-resistant-prostrate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Castrate Resistant Prostrate Cancer Pipeline Report
* Coverage- Global
* Castrate Resistant Prostrate Cancer Companies- Janseen, Bristol-Myers Squibb, AB Science, Newsoara Biopharma, ESSA Pharma, and others.
* Castrate Resistant Prostrate Cancer Therapies- Etrumadenant, Zimberelimab, Quemliclustat, PF-06821497, Pembrolizumab, and others.
* Castrate Resistant Prostrate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Castrate Resistant Prostrate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Castrate Resistant Prostrate Cancer Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Castrate Resistant Prostrate Cancer Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/castrate-resistant-prostrate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Castrate Resistant Prostrate Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Castrate Resistant Prostrate Cancer - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Castrate Resistant Prostrate Cancer Collaboration Deals
* Late Stage Products (Phase III)
* Niraparib: Janseen
* Mid Stage Products (Phase II)
* ZEN003694: Newsoara Biopharma
* Early Stage Products (Phase I)
* EPI7386: ESSA Pharma
* Pre-clinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Castrate Resistant Prostrate Cancer Key Companies
* Castrate Resistant Prostrate Cancer Key Products
* Castrate Resistant Prostrate Cancer- Unmet Needs
* Castrate Resistant Prostrate Cancer- Market Drivers and Barriers
* Castrate Resistant Prostrate Cancer- Future Perspectives and Conclusion
* Castrate Resistant Prostrate Cancer Analyst Views
* Castrate Resistant Prostrate Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=castrate-resistant-prostrate-cancer-pipeline-insights-treatment-drugs-clinical-trials-and-companies-2024]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Castrate Resistant Prostrate Cancer Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024 here
News-ID: 3661647 • Views: …
More Releases from ABNewswire
Cell and Gene Therapy in Parkinson's Disease Market to Experience Notable Growth …
The Key Cell and Gene Therapy in Parkinson's Disease Companies in the market include - Prevail Therapeutics (Eli Lilly), MeiraGTx, Hope Biosciences, and others.
DelveInsight's "Cell and Gene Therapy in Parkinson's Disease Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Cell and Gene Therapy in Parkinson's Disease, historical and forecasted epidemiology as well as the Cell and Gene Therapy in Parkinson's Disease market trends in the…
Polycythemia Vera Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Polycythemia Vera pipeline constitutes 8+ key companies continuously working towards developing 10+ Polycythemia Vera treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Polycythemia Vera Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
Myelofibrosis Market Insights Highlight Expanding Outlook Till 2034, DelveInsigh …
The Key Myelofibrosis Companies in the market include - Lynk Pharmaceuticals, Samus Therapeutics, Taiga Biotechnologies, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Inc., Keros Therapeutics, Inc., Galecto Biotech AB, Actuate Therapeutics Inc., Karyopharm Therapeutics, AbbVie, Sierra Oncology, and others.
DelveInsight's "Myelofibrosis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Myelofibrosis, historical and forecasted epidemiology as well as the Myelofibrosis market trends in the United States, EU4 (Germany, Spain,…
Asthma Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Obser …
The Key Asthma Companies in the market inlcude - GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharmaceuticals, Inc., AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharmaceuticals, Genentech Research, Roche, Suzhou Connect Biopharmaceuticals, Avalo Therapeutics, 4D Pharma plc, Regeneron Pharmaceuticals, RAPT Therapeutics, Inc., Incyte Corporation, Areteia Therapeutics, Suzhou Connect Biopharmaceuticals, Ltd., Cumberland Pharmaceuticals, Pulmatrix Inc., and others.
DelveInsight's "Asthma Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Asthma, historical and…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
